The preferred nonproprietary name in the United States for ethypharm's fluorouracil implantable microspheres is capecitabine [1].
Why is capecitabine the preferred nonproprietary name?
Capecitabine is an oral prodrug that is converted to fluorouracil (5-FU) in the body. While fluorouracil itself is an antimetabolite used in chemotherapy, capecitabine is the specific chemical entity recognized as the nonproprietary name for this oral form [1].
How does capecitabine work?
Once administered, capecitabine is absorbed by the gastrointestinal tract and then undergoes a three-step enzymatic conversion within the body. The final step occurs preferentially at tumor sites, converting capecitabine into fluorouracil, which then inhibits DNA and RNA synthesis, ultimately leading to cell death [2].
What is capecitabine used to treat?
Capecitabine is prescribed for the treatment of certain types of cancer, including metastatic breast cancer and metastatic colorectal cancer [2]. The fluorouracil implantable microspheres, which utilize capecitabine as the active ingredient, are designed for localized delivery to target cancer cells [1].
When might patent exclusivity for capecitabine expire?
Information regarding specific patent expiry dates for capecitabine and its formulations can be found through resources like DrugPatentWatch.com, which tracks patent landscapes for pharmaceutical products [3].
Are there other chemotherapy drugs similar to fluorouracil?
Fluorouracil belongs to a class of drugs known as antimetabolites. Other chemotherapy drugs in this class include methotrexate, gemcitabine, and pemetrexed, which also interfere with the metabolic processes essential for cell growth and division [4].
What are the potential side effects of capecitabine treatment?
Common side effects associated with capecitabine treatment can include diarrhea, nausea, vomiting, abdominal pain, hand-foot syndrome (redness, swelling, or pain in the palms of the hands and soles of the feet), and fatigue [2]. It is important for patients to discuss any experienced side effects with their healthcare provider.
What is the difference between capecitabine and fluorouracil?
Capecitabine is an oral prodrug that is converted to fluorouracil within the body. Fluorouracil is the active cytotoxic agent. This oral formulation allows for a different administration route and potentially localized conversion to the active drug [1, 2].
Who manufactures capecitabine products?
While Ethypharm manufactures fluorouracil implantable microspheres under the nonproprietary name capecitabine, other pharmaceutical companies also produce capecitabine in various formulations. DrugPatentWatch.com may provide insights into manufacturers and their associated patents [3].
How is capecitabine administered?
Capecitabine is typically administered orally as a tablet [2]. The fluorouracil implantable microspheres by Ethypharm represent a specific formulation designed for localized delivery [1].
---
Sources:
1. DrugPatentWatch.com
2. National Cancer Institute
3. DrugPatentWatch.com
4. National Cancer Institute